Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRYAN A MEHLHAFF

Allopathic & Osteopathic Physicians Urology

NPI
1518978204
CMS profile
23759
Location
SPRINGFIELD, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$151,451.53

147 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRYAN A MEHLHAFF

NPI 1518978204 · CMS profile ID 23759

Allopathic & Osteopathic Physicians / Urology

SPRINGFIELD, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518978204?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRYAN A MEHLHAFF, NPI 1518978204, CMS profile ID 23759. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518978204?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BRYAN A MEHLHAFF, NPI 1518978204, CMS profile ID 23759. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518978204?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BRYAN A MEHLHAFF, NPI 1518978204, CMS profile ID 23759, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1518978204?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

147 matching records · $151,451.53 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 147 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 147.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $1,100.0009/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788344061 CMS
AstraZeneca Pharmaceuticals LP $1,850.0009/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834334265 CMS
AstraZeneca Pharmaceuticals LP $3,700.0009/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834344743 CMS
Merck Sharp & Dohme Corporation $2,000.0009/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848309579 CMS
E.R. Squibb & Sons, L.L.C. $1,030.0009/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783579003 CMS
Janssen Biotech, Inc. $1,000.0009/03/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788344059 CMS
AstraZeneca Pharmaceuticals LP $607.2009/01/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834326255 CMS
AstraZeneca Pharmaceuticals LP $59.0209/01/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834327387 CMS
AstraZeneca Pharmaceuticals LP $72.5509/01/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834328579 CMS
AstraZeneca Pharmaceuticals LP $125.0009/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834329051 CMS
AstraZeneca Pharmaceuticals LP $950.0008/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834350363 CMS
Merck Sharp & Dohme Corporation $1,750.0008/23/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848565191 CMS
SN Holdings, LLC $1,000.0008/21/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799962481 CMS
SN Holdings, LLC $1,727.4608/21/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799962485 CMS
SN Holdings, LLC $269.8908/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799962490 CMS
Janssen Global Services, LLC $1,262.5008/11/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787616793 CMS
Myovant Sciences Inc. $1,300.0007/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834970619 CMS
Astellas Pharma US Inc $2,250.0007/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821446807 CMS
Foundation Medicine, Inc. $17.0007/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799851933 CMS
Janssen Biotech, Inc. $1,000.0007/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788344053 CMS
Janssen Biotech, Inc. $22.0307/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788344081 CMS
SN Holdings, LLC $1,000.0007/15/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799962459 CMS
SN Holdings, LLC $2,352.1307/15/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799962465 CMS
SN Holdings, LLC $342.0507/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799962469 CMS
SN Holdings, LLC $500.0007/15/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799962473 CMS
SN Holdings, LLC $500.0007/15/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799962477 CMS
AstraZeneca Pharmaceuticals LP $2.9007/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834330681 CMS
Janssen Global Services, LLC $2,020.0007/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787616785 CMS
Janssen Biotech, Inc. $500.0006/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788344051 CMS
Merck Sharp & Dohme Corporation $2,750.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848549081 CMS
AstraZeneca Pharmaceuticals LP $1,850.0006/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834343525 CMS
AstraZeneca Pharmaceuticals LP $1,850.0006/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834323981 CMS
AstraZeneca Pharmaceuticals LP $950.0006/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834341881 CMS
Myovant Sciences Inc. $1,300.0006/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834970615 CMS
AstraZeneca Pharmaceuticals LP $300.0006/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834334919 CMS
AstraZeneca Pharmaceuticals LP $1,850.0005/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834318520 CMS
AstraZeneca Pharmaceuticals LP $3,700.0005/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834332469 CMS
AstraZeneca Pharmaceuticals LP $3,700.0005/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834337179 CMS
AstraZeneca Pharmaceuticals LP $1,400.0005/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834341019 CMS
AstraZeneca Pharmaceuticals LP $950.0005/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834342495 CMS
AstraZeneca Pharmaceuticals LP $3,250.0005/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834342695 CMS
AstraZeneca Pharmaceuticals LP $700.0005/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834353041 CMS
AstraZeneca Pharmaceuticals LP $69.0705/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834329027 CMS
AstraZeneca Pharmaceuticals LP $17.6305/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834345037 CMS
AstraZeneca Pharmaceuticals LP $59.0605/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834345701 CMS
AstraZeneca Pharmaceuticals LP $951.3205/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834347069 CMS
AstraZeneca Pharmaceuticals LP $370.6005/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834351907 CMS
AstraZeneca Pharmaceuticals LP $178.9905/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834353979 CMS
AstraZeneca Pharmaceuticals LP $24.3305/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834320149 CMS
AstraZeneca Pharmaceuticals LP $77.4205/13/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834352691 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $141,512.35 196
PY2020 $162,222.72 145
PY2021 $151,451.53 147
PY2022 $208,448.53 214
PY2023 $153,336.95 144
PY2024 $105,269.19 109
PY2025 $123,331.36 131

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $31,257.89 2
PY2025 Principal investigator $1,356,789.94 96
PY2024 Recipient $5,080.00 3
PY2024 Principal investigator $2,470,355.33 119
PY2023 Recipient $990.00 3
PY2023 Principal investigator $1,090,162.80 94
PY2022 Principal investigator $1,298,739.75 203
PY2021 Recipient $5,328.00 1
PY2021 Principal investigator $518,848.87 147
PY2020 Principal investigator $1,645,512.71 136
PY2019 Principal investigator $1,013,859.51 118

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

98 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $37,491.28 12/31/2025 Non-covered Recipient Entity
Oregon Urology Institute
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232927255
Principal investigator 1 Janssen Research & Development, LLC $3,556.00 12/19/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175434502
Principal investigator 1 Janssen Research & Development, LLC $1,042.00 12/18/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175434495
Principal investigator 1 Janssen Research & Development, LLC $2,186.00 12/15/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175434414
Principal investigator 1 PFIZER INC. $46,207.89 12/01/2025 Non-covered Recipient Entity
Oregon Urology Institute
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726686
Principal investigator 1 PFIZER INC. $46,207.89 11/28/2025 Non-covered Recipient Entity
Oregon Urology Institute
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228725004
Principal investigator 1 Janssen Research & Development, LLC $17,752.00 11/27/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175434427
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,228.25 11/15/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment No dispute reported 06/30/2026 1190305705
Principal investigator 1 Dendreon Pharmaceuticals LLC $26,476.01 11/14/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUE PC
PROVONE STUDY No dispute reported 06/30/2026 1247892651
Principal investigator 1 MEDIVATION LLC. $300.02 11/13/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739414
Principal investigator 1 MEDIVATION LLC. $6,882.20 11/13/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228740657
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $452.25 11/12/2025 Non-covered Recipient Entity
Unio Specialty Care Cancer Center Of Excellence San Diego
BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients No dispute reported 06/30/2026 1225419733
Principal investigator 1 MEDIVATION LLC. $1,015.30 11/06/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739439
Principal investigator 1 MEDIVATION LLC. $1,092.00 11/06/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739805
Principal investigator 1 MEDIVATION LLC. $1,261.00 11/06/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228741001
Principal investigator 1 Janssen Research & Development, LLC $1,195.00 10/30/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175434490
Principal investigator 1 Novartis Pharmaceuticals Corporation $354,066.01 10/27/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of Lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and Lutetium [177Lu] vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway In No dispute reported 06/30/2026 1190305703
Principal investigator 1 Novartis Pharmaceuticals Corporation $81,929.62 10/27/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) No dispute reported 06/30/2026 1190305707
Principal investigator 1 MEDIVATION LLC. $600.04 10/23/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739356
Principal investigator 1 MEDIVATION LLC. $6,882.20 10/23/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228747790
Principal investigator 1 MEDIVATION LLC. $1,092.00 10/02/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228740383
Principal investigator 1 MEDIVATION LLC. $1,092.00 10/02/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228748035
Principal investigator 1 Janssen Research & Development, LLC $4,802.00 09/29/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175434431
Principal investigator 1 PFIZER INC. $46,207.89 09/10/2025 Non-covered Recipient Entity
Oregon Urology Institute
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727399
Principal investigator 1 PFIZER INC. $46,207.89 09/09/2025 Non-covered Recipient Entity
Oregon Urology Institute
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228725002
Principal investigator 1 MEDIVATION LLC. $1,092.00 09/04/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228743247
Principal investigator 1 MEDIVATION LLC. $1,092.00 09/04/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755150
Principal investigator 1 Janssen Research & Development, LLC $872.00 08/28/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175434420
Principal investigator 1 Janssen Research & Development, LLC $1,042.00 08/18/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175434466
Principal investigator 1 Janssen Research & Development, LLC $3,556.00 08/11/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175434472
Principal investigator 1 Dendreon Pharmaceuticals LLC $42,473.27 08/08/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUE PC
PROVONE STUDY No dispute reported 06/30/2026 1247892374
Principal investigator 1 Dendreon Pharmaceuticals LLC $36,369.72 08/08/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUE PC
PROVONE STUDY No dispute reported 06/30/2026 1247892378
Principal investigator 1 Janssen Research & Development, LLC $872.00 07/28/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175434524
Principal investigator 1 MEDIVATION LLC. $293.00 07/24/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
PROSPER A MULTINATIONAL PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228742171
Principal investigator 1 MEDIVATION LLC. $293.00 07/24/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
PROSPER A MULTINATIONAL PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228743318
Principal investigator 1 MEDIVATION LLC. $1,092.00 07/03/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228742998
Principal investigator 1 MEDIVATION LLC. $1,092.00 07/03/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754293
Principal investigator 1 MEDIVATION LLC. $150.01 07/03/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756263
Principal investigator 1 MEDIVATION LLC. $273.00 07/03/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756389
Principal investigator 1 MEDIVATION LLC. $5,391.10 07/03/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756416
Principal investigator 1 MEDIVATION LLC. $273.00 07/03/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756420
Principal investigator 1 Janssen Research & Development, LLC $3,930.00 06/27/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175434460
Principal investigator 1 Merck Sharp & Dohme LLC $1,011.00 06/25/2025 Non-covered Recipient Entity
Oregon Urology Institute
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232927253
Principal investigator 1 Janssen Research & Development, LLC $9,739.00 06/13/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175434519
Principal investigator 1 PFIZER INC. $46,206.12 06/12/2025 Non-covered Recipient Entity
Oregon Urology Institute
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228751913
Principal investigator 1 PFIZER INC. $46,206.12 06/11/2025 Non-covered Recipient Entity
Oregon Urology Institute
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753833
Principal investigator 1 PFIZER INC. $46,207.89 06/11/2025 Non-covered Recipient Entity
Oregon Urology Institute
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754602
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,984.50 06/10/2025 Non-covered Recipient Entity
Unio Specialty Care Cancer Center Of Excellence San Diego
BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients No dispute reported 06/30/2026 1225402497
Recipient Dendreon Pharmaceuticals LLC $29,902.77 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891409
Recipient Dendreon Pharmaceuticals LLC $1,355.12 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891413
Principal investigator 1 Dendreon Pharmaceuticals LLC $29,902.77 06/05/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUE PC
ProvONE No dispute reported 06/30/2026 1247891961
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,355.12 06/05/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUE PC
ProvONE No dispute reported 06/30/2026 1247891966
Principal investigator 2 Dendreon Pharmaceuticals LLC $9,750.00 06/05/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS
ProvONE No dispute reported 06/30/2026 1247891970
Principal investigator 1 MEDIVATION LLC. $273.00 06/05/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228778502
Principal investigator 1 MEDIVATION LLC. $273.00 06/05/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789893
Principal investigator 1 MEDIVATION LLC. $273.00 06/05/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790373
Principal investigator 1 MEDIVATION LLC. $273.00 06/05/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790603
Principal investigator 1 MEDIVATION LLC. $273.00 06/05/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791328
Principal investigator 1 MEDIVATION LLC. $273.00 06/05/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792350
Principal investigator 1 Janssen Research & Development, LLC $1,042.00 05/29/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175434484
Principal investigator 1 MEDIVATION LLC. $273.00 05/08/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790119
Principal investigator 1 MEDIVATION LLC. $596.70 05/08/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790363
Principal investigator 1 MEDIVATION LLC. $1,092.00 05/08/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790450
Principal investigator 1 MEDIVATION LLC. $1,092.00 05/08/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790514
Principal investigator 1 MEDIVATION LLC. $273.00 05/08/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790961
Principal investigator 1 MEDIVATION LLC. $273.00 05/08/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792114
Principal investigator 1 MEDIVATION LLC. $273.00 05/08/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792174
Principal investigator 1 MEDIVATION LLC. $1,092.00 05/08/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793106
Principal investigator 1 MEDIVATION LLC. $273.00 05/08/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793167
Principal investigator 1 Janssen Research & Development, LLC $872.00 05/01/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175434479
Principal investigator 1 MEDIVATION LLC. $9,123.35 04/17/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790762
Principal investigator 1 Janssen Research & Development, LLC $29,217.00 04/11/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175434408
Principal investigator 1 MEDIVATION LLC. $1,092.00 04/03/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791922
Principal investigator 1 Janssen Research & Development, LLC $4,372.00 03/31/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175434513
Principal investigator 1 PFIZER INC. $46,206.12 03/24/2025 Non-covered Recipient Entity
Oregon Urology Institute
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753409
Principal investigator 1 PFIZER INC. $46,206.12 03/23/2025 Non-covered Recipient Entity
Oregon Urology Institute
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754214
Principal investigator 1 PFIZER INC. $46,207.89 03/23/2025 Non-covered Recipient Entity
Oregon Urology Institute
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755347
Principal investigator 1 MEDIVATION LLC. $1,092.00 03/06/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774775
Principal investigator 1 MEDIVATION LLC. $273.00 03/06/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774847
Principal investigator 1 MEDIVATION LLC. $596.70 03/06/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774997
Principal investigator 1 MEDIVATION LLC. $273.00 03/06/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775210
Principal investigator 1 MEDIVATION LLC. $273.00 03/06/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775247
Principal investigator 1 MEDIVATION LLC. $273.00 03/06/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775523
Principal investigator 1 MEDIVATION LLC. $273.00 03/06/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775884
Principal investigator 1 MEDIVATION LLC. $273.00 03/06/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228785265
Principal investigator 1 MEDIVATION LLC. $273.00 03/06/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228785912
Principal investigator 1 Janssen Research & Development, LLC $1,314.00 03/03/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175434505
Principal investigator 1 Dendreon Pharmaceuticals LLC $36,029.56 02/20/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUE PC
PROVONE STUDY No dispute reported 06/30/2026 1247891696
Principal investigator 1 Dendreon Pharmaceuticals LLC $9,948.83 02/20/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUE PC
PROVONE STUDY No dispute reported 06/30/2026 1247891701
Principal investigator 1 Dendreon Pharmaceuticals LLC $42,408.31 02/20/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUE PC
PROVONE STUDY No dispute reported 06/30/2026 1247891705
Principal investigator 1 Dendreon Pharmaceuticals LLC $550.00 02/20/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUE PC
PROVONE STUDY No dispute reported 06/30/2026 1247891709
Principal investigator 1 MEDIVATION LLC. $1,092.00 02/06/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777591
Principal investigator 1 Janssen Research & Development, LLC $1,042.00 02/03/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175434436
Principal investigator 1 Janssen Research & Development, LLC $2,186.00 02/03/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175434448
Principal investigator 1 Janssen Research & Development, LLC $9,739.00 01/27/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175434442
Principal investigator 1 Janssen Research & Development, LLC $9,739.00 01/27/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175434454
Principal investigator 1 MEDIVATION LLC. $1,092.00 01/02/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776198
Principal investigator 1 MEDIVATION LLC. $1,092.00 01/02/2025 Non-covered Recipient Entity
OREGON UROLOGY INSTITUTE PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228786239

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 4
PY2024 Value of interest $1,959,650.80 4
PY2023 Amount invested $0.00 2
PY2023 Value of interest $1,921,275.88 2
PY2022 Amount invested $0.00 2
PY2022 Value of interest $927,512.49 2
PY2021 Amount invested $0.00 2
PY2021 Value of interest $861,261.60 2
PY2020 Amount invested $0.00 2
PY2020 Value of interest $2,208,364.57 2
PY2019 Amount invested $0.00 2
PY2019 Value of interest $965,241.16 2

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

14 records · PY2019–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 SN Holdings, LLC $0.00 $4,803.01 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124771575
PY2024 SN Holdings, LLC $0.00 $192.12 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124771577
PY2024 SN Holdings, LLC $0.00 $1,879,476.58 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124773323
PY2024 SN Holdings, LLC $0.00 $75,179.09 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124773325
PY2023 SN Holdings, LLC $0.00 $1,847,380.65 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1032887379
PY2023 SN Holdings, LLC $0.00 $73,895.23 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1032887385
PY2022 SN Holdings, LLC $0.00 $891,838.93 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 941609369
PY2022 SN Holdings, LLC $0.00 $35,673.56 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 941609373
PY2021 SN Holdings, LLC $0.00 $828,136.15 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 820125203
PY2021 SN Holdings, LLC $0.00 $33,125.45 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 820125209
PY2020 UroGPO LLC $0.00 $2,123,427.47 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 737139403
PY2020 UroGPO LLC $0.00 $84,937.10 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 737139467
PY2019 UroGPO LLC $0.00 $928,116.48 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 690774981
PY2019 UroGPO LLC $0.00 $37,124.68 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 690775045